Dr. Agarwals Health Care Ltd (AGARWALEYE) Q1FY27 Concall Summary - Jun-2026 Qtr
Performance Overview
- The company reported a record-breaking start to the fiscal year, marked by its highest-ever quarterly launch of 16 new surgical facilities and the strongest sequential revenue growth.
- Overall financial performance was robust, with a 26% year-on-year growth in revenue from operations and a 25.2% increase in EBITDA, demonstrating strong operational momentum.
- The company's Greenfield expansion strategy is accelerating, with 18 new facilities commissioned in the quarter, nearly matching half of the entire previous fiscal year's surgical additions in a single quarter.
- Mature facilities (operational before FY23) continue to be the primary growth engine, contributing 75.9% of group revenues and posting a strong same-store sales growth (SSSG) of 16.3%.
- The company is successfully executing its strategy of deepening market penetration and expanding into new geographies, with significant growth observed across all regions, particularly a 50.5% YoY revenue increase in the North.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.